The retinoblastoma tumor suppressor gene (Rb) has many functions within the cell including regulation of transcription, dierentiation, apoptosis, and the cell cycle. Regulation of these functions is mediated by phosphorylation at as many as 16 cyclin-dependent kinase (CDK) phosphorylation sites in vivo. The contribution of these sites to the regulation of the various Rb functions is not well understood. To characterize the eect of phosphorylation at these sites, we systematically mutagenized the serines or threonines to glutamic acid. Thirty-®ve mutants with dierent combinations of modi®ed phosphorylation sites were assayed for their ability to arrest the cell cycle and for their potential to induce dierentiation. Only the most highly substituted mutants failed to arrest cell cycle progression. However, mutants with as few as four modi®ed phosphorylation sites were unable to promote dierentiation. Other mutants had increased activity in this assay. We conclude that modi®cation of Rb phosphorylation sites can increase or decrease protein activity, that dierent Rb functions can be regulated independently by distinct combinations of sites, and that the eects of modi®cation at any one site are context dependent.
Introduction
Mutational inactivation of the retinoblastoma tumor suppressor gene is the cause of the pediatric cancer retinoblastoma, and deregulation of the Rb-mediated growth control pathway may contribute to the genesis of most human tumors (Goodrich and Lee, 1990; Sherr, 1996) . The Rb protein (pRb) functions to restrict transit of the cell cycle, particularly during the initial stages of G1 (Goodrich et al., 1991; Qin et al., 1992; Sherr, 1996) and possibly during S phase (Knudsen et al., 1998; Chew et al., 1998) . This pRbmediated block to cell proliferation is thought to be a central component of the restriction point and, therefore, important for normal growth and dierentiation (Weinberg, 1990) .
The function of pRb is regulated by phosphorylation. Phosphorylation of pRb inhibits its ability to restrict cell cycle progression (Hinds et al., 1992; Ewen et al., 1993; Dowdy et al., 1993; Connell-Crowley et al., 1997) , to repress transcription (Bremner et al., 1995; Sellers et al., 1995) , and to associate with a number of cellular proteins including the E2F family of transcription factors (Suzuki-Takahashi et al., 1995; Knudsen and Wang, 1997) . The kinases responsible for pRb phosphorylation in vivo likely include members of the cyclin-dependent kinase (CDK) family. Phosphorylation of pRb coincides with the activation of CDKs in vivo (Chen et al., 1989; DeCaprio et al., 1989; Buchkovich et al., 1989; Mihara et al., 1989) , and pRb serves as an ecient substrate for CDKs in vitro (Taya et al., 1989; Lees et al., 1991; Lin et al., 1991; Kato et al., 1993; Knudsen and Wang, 1996; ConnellCrowley et al., 1997) . Since CDKs can phosphorylate pRb in vitro on most, if not all, of the sites that are modi®ed in vivo, they probably play a major role in the regulation of pRb.
Phosphorylation of pRb is complex. There are 16 consensus CDK phosphorylation sites distributed throughout pRb ( Figure 1 ) and most of these are utilized in vivo (Lees et al., 1991) . Seven consensus sites are clustered in the C-terminal domain, two sites reside in the spacer region between the minimal domains required for SV40 T antigen binding, and the remaining sites are in the N-terminal third of the protein. Attempts have been made to unravel the regulation of pRb function by blocking phosphorylation at consensus CDK phosphorylation sites by alanine substitution (Hamel et al., 1992) . Since replacement of serine or threonine with alanine prevents phosphorylation, mutants are assayed for resistance to inactivation by phosphorylation either in vitro or in cells that eciently phosphorylate pRb. Through this type of analysis, the seven sites in the Cterminal domain, the two sites in the spacer region, and some N-terminal sites have all been implicated as being important for regulation of pRb-mediated function (Lukas et al., 1997; Knudsen and Wang, 1997; Chew et al., 1998; Brown et al., 1999) . Phosphorylation of one of the C-terminal sites in vitro, serine 795, is required to inhibit pRb-mediated G1 arrest upon microinjection, although other sites may be required as well . Phosphorylation of either the seven C-terminal sites or the two spacer sites is sucient to inhibit E2F-1 binding in vitro (Knudsen and Wang, 1997) . Phosphorylation of S807 and/or S811 is required for inhibition of pRb/Abl binding in vitro while T821 and/or T826 phosphorylation is necessary to prevent pRB/SV40 T antigen association in vitro (Knudsen and Wang, 1996) .
The contribution of individual phosphorylation sites to regulation of Rb function is less clear since, with the exception of S795, no single site has been demonstrated to be required for regulation of pRb function in cells.
This observation may indicate that regulation of pRb occurs by accumulation of a threshold quantity of phosphorylated residues (Brown et al., 1999) . Alternatively, qualitative dierences in the eects of phosphorylation at individual sites may go unnoticed because of potential complications in alanine substitution experiments. For example, phosphorylation may not uniformly decrease protein activity. Phosphorylation at some sites may activate, rather than inhibit, a particular pRb function. Also, blocking phosphorylation at one site may aect the eciency with which remaining wild-type sites are phosphorylated in vitro or in cells. Alanine substitution at S795, for example, alters the sites phosphorylated by cyclin D1/CDK4 in vitro . The ability of the remaining, wild-type sites to be phosphorylated may also vary depending on the cell line or kinase preparation used. Finally, the eects of phosphorylation at a particular site may depend on the context of other modi®ed sites. The impact of modi®cation at one site, therefore, may be revealed under some circumstances but not others.
An alternative approach to phosphorylation site analysis is glutamic acid substitution mutagenesis. The rationale for this analysis is based on the assumption that glutamic acid mimics the structure of a phosphorylated serine or threonine residue. In contrast to alanine substitution, glutamic acid substitution has the potential to directly assess the eects of modi®cation at particular sites without the need for additional phosphorylation in vitro or in cells. We have systematically mutated serine or threonine residues at consensus CDK phosphorylation sites to glutamic acid. A collection of 35 mutants with varying combinations of modi®ed phosphorylation sites has been tested in two assays of Rb function. We con®rm the importance of multiple C-terminal and spacer region sites for Rbinduced cell cycle arrest as ®rst determined by alanine substitution mutagenesis. Unexpectedly, the ability of pRb to induce dierentiation is inactivated by as few as four modi®ed sites and mutants containing as many as six modi®ed sites have increased activity. These ®ndings raise the possibility that phosphorylation may activate, as well as inactivate, pRb function and that dierent functions of pRb may be regulated independently by phosphorylation of particular combinations of sites.
Results

Rb glutamic acid substitution mutants
The Rb protein contains 16 consensus CDK phosphorylation sites (Figure 1 ). Seven of these sites are contained within a 50 amino acid stretch within the C-terminal domain of the protein. This domain is sucient for c-Abl binding (Welch and Wang, 1993) and is required for association with many non-LXCXE containing pRb-associated proteins like E2F-1 (Huang et al., 1992; Qin et al., 1992) . Two sites are located in the spacer region between the A and B domains. The A and B domains comprise the minimal sequence required for association with SV40 T antigen (Huang et al., 1990; Hu et al., 1990) . One site, S563, is located within the A domain but its phosphorylation in vivo is uncon®rmed. The remaining sites are distributed throughout the N-terminal third of the protein. The function of the N-terminal region is unknown since the A, B, spacer, and C domains are sucient for activity in most assays of pRb function. This region is, however, required for normal biological function in vivo (Riley et al., 1997) . Regions of this N-terminal domain are required for association with three known cellular proteins whose signi®cance for Rb function are uncharacterized (Durfee et al., 1994; Inoue et al., 1995; Sterner et al., 1998) .
We chose to focus our mutagenesis on 12 of the consensus sites including the seven C-terminal sites, the two spacer region sites, and three sites within the Nterminal domain. These sites were chosen based on the criteria that they are con®rmed phospho-acceptors in vivo. Using site-directed mutagenesis 35 mutants were created with various combinations of the serines or threonines substituted with glutamic acid (Figure 1 ). The name of each of the mutants was based on the total number of mutated phosphorylation sites with dierent combinations of the same number of sites designated by Figure 1 Glutamic acid substitution mutations made in Rb phosphorylation sites. A schematic of pRb is presented at the top indicating the extent of the A, B, and C domains. Wild-type pRb contains 16 consensus proline-directed phosphorylation sites indicated by arrowheads. The amino acid residue and number of each phosphorylation site is listed. The phosphorylation site mutants described in this study are shown, with the particular sites mutated to glutamic acid in each mutant indicated by a ®lled square. The names of each mutant indicate the total number of glutamic acid substitutions contained in that mutant. Mutants are constructed as described in Materials and methods. All mutants, except 56M10, are expressed as full-length proteins. Translation of 56M10 likely begins M379 producing a protein that lacks the N-terminal third of wild-type Rb A, B, C, etc. The mutants were all expressed in the same vector under control of the cytomegalovirus promoter and the small T antigen polyadenylation site. All of the mutants, except 56M10, were expressed as full-length proteins. The 56M10 mutant expresses an N-terminally truncated form of the M10 mutant that retains the A, spacer, B, and C domains.
Expression of mutant Rb proteins
Extracts containing equivalent amounts of total cell protein prepared from transfected 293 cells (Figure 2 ) were resolved by SDS ± PAGE. Rb protein was detected by Western blotting and staining with an anti-pRb rabbit polyclonal antibody. Although 293 cells expressed endogenous pRb, under the conditions used endogenous protein was undetectable. Most of the mutants expressed protein at a level approximately equal to that of wild-type pRb.
Although most of the mutants expressed similar levels of protein, there were some notable exceptions. The M10, M9 and M3 mutants expressed lower levels of pRb. Several mutants did not express any detectable protein. These mutants included M6A, M5C, M4B, M4C, and M4D. Even upon Western analysis of greater amounts of total protein where endogenous pRb was detectable, no increase in pRb above endogenous levels could be detected in cells transfected with the M5C mutant (D Goodrich, 1999, unpublished observations) . The failure of the M5C mutant to make a detectable level of full-length protein was reproducible in multiple, independent transfections. Qualitatively similar results were observed in SAOS-2 cells, although the general level of protein expression detected was lower, likely because of lower transfection eciencies (D Goodrich, 1999, unpublished observations) .
Since the various mutant expression vectors were identical, excepting the base changes at the mutated codons, we considered the possibility that lack of expression in some mutants was due to inecient transcription or translation unlikely. However, lack of detectable protein expression from such mutants could be due to acquisition of inadvertent mutations. To rule out this possibility, we sequenced the entire Rb cDNA from the M5C mutant and found that its nucleotide sequence was identical to the sequence of the wild-type pRb cDNA, excepting the changes at the altered phosphorylation sites (S Barrientes, 1999, unpublished observations) .
Rb protein function is inhibited by glutamic acid substitution at phosphorylation sites
A number of the mutants have been analysed for their activity in the`¯at cell' assay upon transfection of the indicated Rb expression vectors and pEGFP-C1 into SAOS-2 cells. In this assay the appearance of isolated, non-dividing cells with a characteristic¯at morphology is counted after selection of successfully transfected cells by growth in the presence of G418 for 2 weeks. These¯at cells typically express markers indicative of dierentiation, hence the assay is a measure of the ability of pRb to promote dierentiation and is distinct from the ability of pRb to arrest G1 cell cycle progression (Sellers et al., 1998) . Since activity in this assay is directly proportional to transfection eciency, we determined transfection eciency for each culture 1 day post-transfection by counting the percentage of GFP-positive cells (data not shown). Transfection eciencies ranged from 8 ± 10% in dierent experiments, but there was no consistent dierence among the various mutant plasmids that would potentially bias the results.
Several of the mutants tested were de®cient in¯at cell formation with activity indistinguishable from the empty vector control (Figure 3 ). While several of the most highly substituted mutants like M12, M8, and M7 were inactive, there was no correlation between the total number of sites mutated and activity. For example, M10 demonstrated activity comparable to pRb while M4E had no detectable activity above the empty vector control. Several of the mutants showed activity that was signi®cantly greater than pRb, in particular mutants M6 and M2B. These mutants consistently generated threefold the number of¯at cells generated by pRb. Other mutants, such as M3 and M3D, generated a quantity of¯at cells intermediate between wild-type pRb and empty vector control, although M3 activity may be low because of low protein expression (see above). As expected, mutants that failed to produce detectable Rb protein, including M5C, were also unable to eciently producē at cells in this assay.
Cell cycle arrest induced by pRb mutants Wang (1996, 1997) The dierences in the behavior of particular mutants in each of the assays may, in part, re¯ect the sensitivity of the dierent assays to a given amount of pRb. In this case, mutants with diminished activity might go undetected if the amount of protein expressed was in vast excess of that required to elicit a response. To address this possibility, we determined the sensitivity of the cell cycle arrest assay to the amount of Rb plasmid DNA used in the transfection. Both the¯at cell and cycle arrest assays were performed with 25 ± 27 mg of Rb DNA in a total of 30 mg DNA per transfection. While keeping the total amount of DNA constant, we titrated the amount of wild-type Rb expression plasmid DNA used and measured the increase in percentage of G1 cells in transfected SAOS-2 cells. A maximum increase in the percentage of G1 cells was achieved Figure 4 Cell cycle arrest assay of Rb phosphorylation site mutants at high ratios of Rb to total DNA. The indicated mutant expression plasmids were assayed for G1 phase cell cycle arrest activity as described in Materials and methods using 27 mg of expression plasmid DNA in a transfection containing 30 mg total DNA. The increase in the percentage of G1 cells in transfected cells relative to untransfected cells is shown. The values are normalized to the CMV negative control which was set to zero. The results are the mean of at least three independent experiments with error bars of one standard deviation from the mean Figure 5 G1 phase cell cycle arrest assayed at low ratio of Rb to total DNA. (a) The Rbwt expression plasmid was assayed for G1 phase cell cycle arrest as described in Materials and methods using the indicated amount of expression plasmid DNA in a transfection containing 30 mg total DNA. The increase in the percentage of G1 cells in transfected cells relative to untransfected cells is shown. The values are normalized to the CMV control which was set to zero. The results are the mean of at least three independent experiments with error bars of one standard deviation from the mean. (b) The indicated mutant expression plasmids were assayed for G1 phase cell cycle arrest activity as described in Materials and methods using 2 ± 3 mg of expression plasmid DNA in a transfection containing 30 mg DNA. The increase in the percentage of G1 cells in transfected cells relative to untransfected cells is shown. The values are normalized to the CMV negative control which was set to zero. The results are the mean of at least three independent experiments with error bars of one standard deviation from the mean Phosphorylation site mutagenesis alters Rb function S Barrientes et al with as little as 2 ± 3 mg of pCMVRbwt DNA in a transfection using a total of 30 mg DNA (Figure 5a ).
We then tested selected mutants for cell cycle arrest using 2 ± 3 mg of Rb expression vector in a transfection containing 30 mg total DNA. Under these conditions, mutants M12, 56M10, M9, and M8 all caused a smaller increase in the percentage of G1 cells than wild-type pRb (Figure 5b ). However, with the possible exception of M12 they still caused an increase in the percentage of G1 cells relative to the empty vector control. Other mutants behaved similarly to wild-type pRb, including mutant M7 and M4E, both of which expressed stable protein but were inactive in the¯at cell assay. Hence, some pRb mutants were clearly active for cell cycle arrest at minimum threshold levels of transfected DNA while they were inactive in inducing¯at cells at high levels of transfected DNA. Other mutants, like M12, M9 and M8, had partially compromised cell cycle arrest activity and undetectablē at cell activity. Most of the remaining mutants, including mutants containing one or two phosphorylation site alterations, were as active as wild-type Rb protein in both¯at cell and cell cycle arrest assays. A summary of the results is presented in Table 3 .
Discussion
Interpretation of the experiments presented here is based on the assumption that glutamic acid substitution mimics the phosphorylated state of the native serine or threonine residues. Since most of the mutants did retain some activity, it is unlikely that the glutamic acid substitutions drastically altered the structure of the protein. Previous work has shown that Rb mutants substituted with other amino acids, including alanine, arginine, and proline, at phosphorylation sites also retain activity (Knudsen and Wang, 1997; Brown et al., 1999) . Flexibility in the structure of the protein in regions containing phosphorylation sites is also consistent with the available crystallographic data (Lee et al., 1998) . The assumption also requires that the negative charge introduced by glutamic acid substitution has eects similar to phosphorylation of the native serine or threonine residues. There is ample precedent for this in the literature for a number of proteins (Ducommun et al., 1991; Maciejewski et al., 1995; Pearson et al., 1995; Engel et al., 1995; Knauf et al., 1996; Yang et al., 1998; Chen et al., 1999) . The fact that our results are consistent, in general, with previous ®ndings using alternative approaches suggests that this is also true for pRb.
The seven C-terminal sites and the two spacer region sites have previously been implicated by alanine M2A  M2B  M2C  M2D  M2E  M2F  M3  M3A  M3B  M3C  M3D  M4  M4B  M4C  M4D  M4E  M5  M5A  M5B  M5C  M6  M6A  M6B  M6C  M7  M8  M9  M10  M12   788E  795E  821E  821E  788E  821E  608E+612E  612E  612E  612E  788E  821E  612E  612E  612E  373E  S788  S795  S608+612E  608E+S612  807E+811E  373E  807E+S811  608E+612E  373E  807E+S811  807E+811E  373E  608E+612E  373E  826E  780E M2C  M2B  M2  M2A  M3  M5C  M5C  M5C  M5C  M3  M4A  M4A  M3  M5C  M5C  M4A  M5  M5  M7  M8 The oligonucleotide used for mutagenesis as listed in Table 1. c The mutant single stranded M13 DNA used as template for mutagenesis (Knudsen and Wang, 1997; Brown et al., 1999) . C-terminal sites are also important for binding c-Abl as well as proteins that utilize the LXCXE motif, like SV40 T antigen (Knudsen and Wang, 1996) . Our results also indicate that C-terminal and spacer region sites are important for regulation of Rb function. For example, multiple phosphorylation site modi®cations in the C-terminus and spacer region are required to compromise the ability of Rb to arrest cell cycle progression. Only the most highly substituted mutants, such as M12, M9, and M8, have decreased ability to arrest SAOS-2 cells in G1. Further, the minimum number of modi®cations necessary to compromise¯at cell activity among the mutants tested is four (M4E), and these four include both spacer region and C-terminal sites. Of these four, S788E and S795E are the only modi®cations conserved in all of the mutants with compromised¯at cell activity, suggesting that these two sites may be particularly important for the regulation of this function. ConnellCrowley et al. (1997) also de®ned S795 as a site whose phosphorylation is required for inactivation of pRb function in a microinjection assay and S788 as a preferred substrate for both cyclin D1/Cdk4 and cyclin A or E/Cdk2 in vitro. The data presented here also con®rm the ®nding that N-terminal sites can in¯uence the regulation of Rb function (Brown et al., 1999) . For example, M10 demonstrates activity in both the¯at cell and cell cycle arrest assays. Addition of the N-terminal modi®cations S249E and S252E to M10 results in M12 that is de®cient in both¯at cell and cell cycle arrest assays. While the data con®rmed the importance of Cterminal, spacer region, and N-terminal sites, several unexpected observations were made as well. First, there was no strict correlation between the number of sites modi®ed and the activity of the protein. Several mutants with a large number of modi®ed sites had greater activity than mutants with fewer phosphorylation site modi®cations. For example, M10 with ten modi®ed sites had greater¯at cell activity than M4E containing four modi®ed sites. M10 contained all the modi®cations in M4E as well as six others. M8 was de®cient in¯at cell activity but adding the T826E modi®cation to create M9 resulted in a protein with signi®cant¯at cell activity. The M9 mutant was de®cient in cell cycle arrest activity at low levels of transfected DNA. Addition of the S780E modi®cation to create M10 increased cell cycle arrest activity to wild-type pRb levels. These ®ndings suggest that phosphorylation of Rb protein can increase, as well as decrease, activity. Second, the eects of modi®cation at any one site were context dependent. For example, addition of the S780E modi®cation to M9 creates M10 with greater cell cycle arrest activity. However the addition of S780E had no eect on a mutant protein lacking the N-terminus (56M10) or on a full-length protein containing the S249E/S252E modi®cations in the N-terminus (M12). Knudsen and Wang (1997) also observed variable eects of C-terminal phosphorylation site modi®cation depending on the status of the Nterminus. Finally, exogenous protein expression could not be detected by Western blot analysis of extracts from cells transfected with the M6A, M5C, M4B, M4C, and M4D mutants. DNA sequencing and the fact that several plasmids derived from these mutant vectors did express Rb protein ruled out inadvertent mutation as being responsible for this observation. Another possibility was that the mutations introduced destabilized Rb protein. If true, phosphorylation of particular sites on Rb may target it for proteolysis. There is precedent for this since phosphorylation targets the Rb family member p130 for destruction by the 26S proteasome (Smith et al., 1998) . Interestingly, all ®ve of these mutants contained the S612E and T821E mutations and at least two of the S608E, S788E, or S795E mutations. Mutants containing modi®cations in addition to these, such as M6, expressed detectable Rb protein. Sellers et al. (1998) has observed that some nonphosphorylation site mutants are defective for G1/S control yet are able to promote dierentiation. Our results extend these ®ndings by characterization of mutants that are active in G1/S control yet are de®cient in promotion of dierentiation. M4E and M7, for example, are as active as wild-type Rb in arresting cell cycle progression yet are inactive in the M12  M10  56M10  M9  M8  M7  M6  M6A  M6B  M6C  M5  M5A  M5B  M5C  M4  M4A  M4B  M4C  M4D  M4E  M3  M3A  M3B  M3C  M3D  M2  M2A  M2B  M2C  M2D  M2E  M2F  788  795 Figure 3 . ++, 50 ± 100% expression relative to Rbwt: +, less than 50% expression relative to Rbwt: 7, no detectable expression: N.D., not determined. c From Figure 2 . +++, greater than 150% Rbwt activity: ++, 50 ± 150% Rbwt activity: +, less than 50% Rbwt activity, but greater than CMV control: 7, less than or equal than CMV control: N.D., not determined.
d From Figures 4/6 . ++, greater than 15% increase in % G1 cells: +, 5 ± 15% increase in % G1 cells: 7, less than 5% increase in % G1 cells: N.D., not determined Phosphorylation site mutagenesis alters Rb function S Barrientes et al ¯at cell assay. These results demonstrate that pRb has multiple, independent functional activities. Our results further extend this ®nding by suggesting that these independent functional activities can be regulated independently by targeting phosphorylation to speci®c subsets sites. Rb protein, therefore, may coordinate cell growth by integrating dierent regulatory pathways whose signals terminate in site-speci®c pRb phosphorylation.
Is phosphorylation of a threshold number of qualitatively similar sites important for pRb regulation, or are the eects of phosphorylation at each site qualitatively distinct? The answer seemingly depends on the particular function of pRb assayed. Our results are consistent with previous studies in suggesting that an accumulation of modi®ed sites with qualitatively indistinguishable eects is important for regulating the ability of pRb to bind E2F-1 and inhibit G1 phase cell cycle progression (Knudsen and Wang, 1997; Brown et al., 1999) . On the other hand, the eects of modi®ca-tion at particular sites on¯at cell activity are clearly qualitatively dierent. Of the mutants analysed in this study, a minimum of four phosphorylation site modi®cations is required to abolish¯at cell activity. However, many mutants with four or more modi®ed sites retain or have increased¯at cell activity. Further, some modi®cations seem to increase¯at cell activity rather than decrease activity. Hence the identity of the sites modi®ed is more important than the number of sites modi®ed. It is apparent in both assays that the eect of modi®cation at any one particular site is dependent on the context of other modi®ed sites and the presence of the N-terminus.
We conclude that phosphorylation of multiple Cterminal and spacer region sites is important for regulation of the ability of pRb to inhibit cell cycle progression, con®rming previous work utilizing alanine substitution mutagenesis. These results are consistent with a quantitative model of Rb regulation by phosphorylation. In contrast, regulation of the ability of pRb to promote dierentiation can be regulated by as few as four speci®c sites and some modi®cations increase protein activity indicating that the eect of phosphorylation at dierent sites is qualitatively distinct. We conclude that the eect of phosphorylation at any one site is likely to be dependent on the function being assayed as well as the context of other modi®ed sites. Our results also place into question the widely held assumption that highly phosphorylated, hyperphosphorylated,' pRb that is typically recognized by altered electrophoretic mobility is completely inactive. Finally, our results suggest that functions of pRb that operate independently of one another (Sellers et al., 1998) , can also be regulated independently by phosphorylation.
Materials and methods
Cell culture and transfections SAOS-2 human osteogenic sarcoma cells and 293 human embryonic kidney cells were obtained from the American Type Culture Collection and were cultured in DMEM containing 10% fetal bovine serum (FBS) and antibiotics at 378C with 5% CO 2 . Cells were prepared for transfection by passage 1 : 4 one day prior to use and a change to fresh media 2 h before transfection. Transfections were performed using the calcium phosphate precipitate method essentially as described (Wigler et al., 1979) . Brie¯y, 30 mg of DNA total was used to prepare the DNA precipitate that was incubated with cells for 16 h (SAOS-2) or for 4 ± 6 h (293). Precipitate was removed and the cells were washed 16 with phosphate buered saline (PBS), 16 brie¯y with PBS+2.5 mM EDTA, and 16 PBS before being re-fed with fresh media. The EDTA was omitted for transfections with 293 cells.
Expression plasmids and mutagenesis
The full-length human Rb coding sequence with a BamHI site engineered at the 5' end and a HindIII site engineered at the 3' end was subcloned into pCMV, a plasmid containing the cytomegalovirus early promoter and the small T antigen polyadenylation signal. The EcoRI-HindIII restriction fragment containing 10 of the 12 sites analysed, was subcloned into M13 mp18 and the resulting plasmid used to generate single-stranded DNA for mutagenesis. For modi®cation of sites S249 and T252, an M13 clone containing the N-terminal Rb sequences was used (Leng et al., 1997) . Mutagenesis was performed using the Sculptor In Vitro Mutagenesis Kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA) as directed by the manufacturer. The oligonucleotide primers used for mutagenesis are listed in Table 1 . The template and primer used for the construction of each particular mutant is listed in Table 2 . DNA sequencing of the M13 various clones con®rmed the presence of the desired mutations. Expression vectors containing these various mutants were constructed by inserting the EcoRI-HindIII restricted 1.8 kbp fragment from the successfully mutated, double-stranded M13 DNA into EcoRI-HindIII restricted pCMVRbwt. The M4A mutant was made by inserting the EcoRI-MluI fragment from M2C into EcoRI-MluI restricted M2A. The 56M10 mutant expression vector was cloned by inserting the EcoRI-HindIII C-terminal mutant fragment directly into the EcoRI-HindIII restricted pCMV. This vector expresses a protein that likely begins at the ®rst in-frame methionine at amino acid residue 379 of the wild-type protein. The M12 mutant was generated using the N-terminal Rb M13 clone as template and the 249E+252E oligonucleotide as primer. The successfully mutated Nterminal fragment was subcloned with the EcoRI-HindIII C-terminal fragment from the M10 mutant into pCMV.
Rb assays
Cell cycle analysis was performed on one 10 cm dish of SAOS-2 (approximately 3610 6 cells) cells for each sample cotransfected as above with a Rb expression plasmid (2 ± 27 mg), pCMVCD20 (3 mg), and pCMV to 30 mg total DNA. Two days following transfection, cells were removed from dishes by treatment with 2.5 mM EDTA and cell suspensions stained for CD20 by incubation for 30 min with 20 ml of undiluted FITC-conjugated anti-CD20 (Becton-Dickinson, Franklin Lakes, NJ, USA) on ice. Cell suspensions were washed with PBS and ®xed by addition of ice-cold 95% EtOH. Cells were stored in EtOH at 7208C until processing for¯ow cytometry. EtOH ®xed cells were washed in PBS, resuspended in PBS+10 mg/ml propidium iodide and 250 mg/ ml RNAse A, and incubated for 30 min at 378C prior to¯ow cytometry. Flow cytometry was performed using a Coulter EPICS Pro®le instrument. At least 2000 FITC positive cells were analysed. The cell cycle pro®les were determined by analysis of the cytometry data with Multicycle (Phenix Flow Systems, San Diego, CA, USA). Flat cell assays were performed by cotransfecting SAOS-2 cells on 10 cm plates with 25 mg of Rb expression vector and 5 mg of pEGFP-C1 (Clontech, Palo Alto, CA, USA). Stable transfectants were selected by growth in regular media plus 500 mg/ml G418 for 2 weeks. The total number of GFP-positive¯at cells was Western blotting 293 cells were transfected with 27 mg Rb expression vector DNA and 3 mg pEGFP-C1 DNA. Transfection eciency was checked the following day by determining the percentage of GFP positive cells by counting under¯uorescent microscopy. Transfection eciencies ranged from 25 ± 35%. Two days following transfection, cells were collected and resuspended in lysis buer containing 50 mM Tris, pH 7.4, 250 mM NaCl, 5 mM EDTA, 0.1% NP-40, 50 mM NaF, 1 mM PMSF, 1 mg/ ml leupeptin. Cells were lysed by three cycles of freezing and thawing. Cell debris was pelleted by centrifugation and the total protein concentration of the soluble extract determined by Bradford assay according to manufacturer's instructions (BioRad, Hercules, CA, USA). Twenty mg of total soluble protein for each sample, normalized for transfection eciency, was loaded on 7.5% SDS-polyacrylamide gel. After electrophoresis, the proteins were transferred to nitrocellulose and the blot blocked with a solution of 5% dried milk powder in TTBS (100 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 1 h at room temperature. The blot was incubated with primary antibody diluted in fresh TTBS for 1 h at room temperature of 48C overnight. Primary antibody was detected using a peroxidase-conjugated secondary antibody and enhanced chemiluminescence (ECL) as described by the manufacturer (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Under the conditions used, endogenous Rb protein in 293 cells was undetectable.
